- Report
- July 2024
- 95 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- June 2023
- 74 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2023
- 140 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Report
- February 2023
- 248 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Report
- November 2021
- 145 Pages
Global
From €3378EUR$3,712USD£2,896GBP
- Book
- February 2023
- 672 Pages
- Book
- May 2021
- 288 Pages
- Book
- April 2018
- 464 Pages
- Book
- February 2016
- 448 Pages

Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive procedure used to treat aortic valve stenosis, a condition in which the aortic valve does not open properly. During the procedure, a catheter is inserted through a small incision in the groin and guided to the heart. A replacement valve is then inserted through the catheter and implanted in the aortic valve. TAVI is a relatively new procedure, having been approved by the FDA in 2011, and is an alternative to traditional open-heart surgery.
TAVI is a rapidly growing market within the cardiovascular devices industry. It is a less invasive procedure than open-heart surgery, and is associated with fewer complications and shorter recovery times. It is also more cost-effective than traditional surgery, making it an attractive option for many patients.
Some of the major companies in the TAVI market include Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott. Show Less Read more